

- Leandro MJ, de la Torre I. 2009.** Translational mini-review series on B cell-directed therapies: the pathogenic role of B cells in autoantibody-associated autoimmune diseases—lessons from B cell-depletion therapy. *Clinical & Experimental Immunology* 157(2):191–197 DOI 10.1111/j.1365-2249.2009.03978.x.
- Makatsori M, Kiani-Alikhan S, Manson A, Verma N, Leandro M, Gurugama NP, Longhurst HJ, Grigoriadou S, Buckland M, Kanfer E, Hanson S, Ibrahim MA, Grimbacher B, Chee R, Seneviratne SL. 2014.** Hypogammaglobulinaemia after rituximab treatment—incidence and outcomes. *QJM* 107(10):821–828 DOI 10.1093/qjmed/hcu094.
- Marinaki S, Kälsch A-I, Grimminger P, Breedijk A, Birck R, Schmitt WH, Weiss C, van der Woude FJ, Yard BA. 2006.** Persistent T-cell activation and clinical correlations in patients with ANCA-associated systemic vasculitis. *Nephrology Dialysis Transplantation* 21(7):1825–1832 DOI 10.1093/ndt/gfl097.
- Mélet J, Mulleman D, Goupille P, Ribourtout B, Watier H, Thibault G. 2013.** Rituximab-induced T cell depletion in patients with rheumatoid arthritis: association with clinical response. *Arthritis & Rheumatism* 65(11):2783–2790 DOI 10.1002/art.38107.
- Ram R, Ben-Bassat I, Shpilberg O, Polliack A, Raanani P. 2009.** The late adverse events of rituximab therapy—rare but there! *Leukemia & Lymphoma* 50(7):1083–1095 DOI 10.1080/10428190902934944.
- Sailler L, Attane C, Michenot F, Canonge J-M, Rostaing L, Arlet-Suau E, Arlet P, Launay F, Montastruc J-L, Lapeyre-Mestre M. 2008.** Rituximab off-label use for immune diseases: assessing adverse events in a single-centre drug-utilization survey. *British Journal of Clinical Pharmacology* 66(2):320–322 DOI 10.1111/j.1365-2125.2008.03193.x.
- Sfikakis PP, Boletis JN, Lionaki S, Vigiaklis V, Fragiadaki KG, Iniotaki A, Moutsopoulos HM. 2005.** Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. *Arthritis & Rheumatism* 52(2):501–513 DOI 10.1002/art.20858.
- Smith RM, Jones RB, Guerry M-J, Laurino S, Catapano F, Chaudhry A, Smith KGC, Jayne DRW. 2012.** Rituximab for remission maintenance in relapsing ANCA-associated vasculitis. *Arthritis & Rheumatism* 64(11):3760–3769 DOI 10.1002/art.34583.
- Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CGM, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U, RAVE-ITN Research Group. 2010.** Rituximab versus cyclophosphamide for induction of remission in ANCA-associated vasculitis. *New England Journal of Medicine* 363(3):221–232 DOI 10.1056/NEJMoa0909905.
- Thurlings RM, Vos K, Wijbrandts CA, Zwinderman AH, Gerlag DM, Tak PP. 2008.** Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. *Annals of the Rheumatic Diseases* 67(7):917–925 DOI 10.1136/ard.2007.080960.
- Wilde B, Thewissen M, Damoiseaux J, van Paassen P, Witzke O, Tervaert JWC. 2010.** T cells in ANCA-associated vasculitis: what can we learn from lesional versus circulating T cells? *Arthritis Research & Therapy* 12(1):204 DOI 10.1186/ar2923.